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Abstract
Background: The majority of people with cancer have at least one other chronic health condition. With each
additional chronic disease, the complexity of their care increases, as does the potential for negative outcomes
including premature death. In this paper, we describe cancer patients’ clinical complexity (i.e., multimorbidity; MMB)
in order to inform strategic efforts to improve care and outcomes for people with cancer of all types and
commonly occurring chronic diseases.
Methods: We conducted a population-based, retrospective cohort study of adults diagnosed with cancer between
2003 and 2013 (N = 601,331) identified in Ontario, Canada healthcare administrative data. During a five to 15-year
follow-up period (through March 2018), we identified up to 16 co-occurring conditions and patient outcomes for
the cohort, including health service utilization and death.
Results: MMB was extremely common, affecting more than 91% of people with cancer. Nearly one quarter (23%) of
the population had five or more co-occurring conditions. While we saw no differences in MMB between sexes,
MMB prevalence and level increased with age. MMB prevalence and type of co-occurring conditions also varied by
cancer type. Overall, MMB was associated with higher rates of health service utilization and mortality, regardless of
other patient characteristics, and specific conditions differentially impacted these rates.
Conclusions: People with cancer are likely to have at least one other chronic medical condition and the presence
of MMB negatively affects health service utilization and risk of premature death. These findings can help motivate
and inform health system advances to improve care quality and outcomes for people with cancer and MMB.
Keywords: Cancer, Multimorbidity, Chronic disease, Health service utilization, Mortality
Introduction
Multimorbidity (MMB), defined as the co-occurrence of
multiple chronic conditions, is a public health crisis,
challenging healthcare systems and affected individuals
and their families [1–5]. The risk of MMB is particularly
high among people with cancer [4, 6–10]. In Ontario,
Canada, more than 75% of people with cancer have at
least one of 16 other prevalent chronic conditions [4].
Rates of MMB among cancer patients, however, vary by
cancer type [6, 11, 12]. Similarly, the chronic condi-
tion(s) that co-occur with cancer also vary by cancer
type and can have different impacts on patient out-
comes, including death [11, 13, 14].
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MMB impacts people with cancer directly through an
increased physiological burden of disease and/or indirectly
through healthcare factors related to treatment decision-
making and the increased complexity of care [15]. For ex-
ample, MMB can complicate and delay cancer and other
diagnoses, increase treatment complexity, risk of poly-
pharmacy, and/or create other redundancies in care [16–
20]. Cancer patients with MMB are less likely to be of-
fered active or curative therapies [21–23], despite growing
evidence that such treatments can be tolerated and effect-
ive for some patients [24–26]. People with cancer and
MMB likely also experience increased burden from man-
aging multiple appointments and care regimens, which
may result in confusion, stress, difficulty adhering to treat-
ment protocols, and poor quality of life.
Another critical challenge to effectively treating and
improving outcomes for people with cancer and other
chronic conditions is that most care plans follow a single
disease-oriented approach [10, 18, 27, 28]. In such
single-disease models, the management of co-occurring
conditions often takes a backseat to cancer even when
coordinated management of chronic conditions could
help improve patient outcomes and quality of life [29,
30]. Well-documented gaps in clinical guidelines and
care management frameworks demonstrate the need for
intentional integration and coordination of cancer and
chronic disease care, including clear direction to pro-
viders who may lack clarity about their roles and respon-
sibilities [31–33] for patients receiving services spanning
siloed specialized and primary care settings [2, 34–36].
In order to improve care and outcomes for people with
cancer and MMB, health care systems must recognize and
reorganize care delivery in order to provide whole-person
care. However, few large epidemiological studies have ex-
amined the overall extent of MMB among people with
cancer of all types to provide guidance about how care
should be improved. Similarly, researchers have not
broadly documented the potential impact of cancer MMB
on health service utilization at the general population level
in order to motivate care delivery reform.
In this paper, we address these research gaps by describing
the co-occurrence of cancer of any type with 16 common
chronic diseases, as well as the level of MMB associated with
patients’ health service utilization in an Ontario, Canada
population-based, retrospective cohort study. In a second,
companion paper using this same data set, we examine
which conditions are most likely to co-occur with cancer
and how specific disease clusters impact patient outcomes
(Koné et al., under review).
Methods
Study design and data sources
We performed a retrospective cohort study of people di-
agnosed with cancer in Ontario, Canada using
population-based healthcare administrative data. The
province of Ontario provides universal coverage of phys-
ician visits and hospital services for virtually all resi-
dents. This study population includes all individuals 18
years and older living in Ontario with a valid health
card, who received a cancer diagnosis between April 1,
2003 and March 31, 2013. Individuals were then
followed-up through March 31, 2018 in order to track
the occurrence of 16 co-occurring chronic health condi-
tions and health service utilization (HSU).
As in our previous work [4], data came from the Insti-
tute for Clinical Evaluative Sciences (ICES) linked data
sets including information from: The Registered Persons
Database (RPDB), the Canadian Institute for Health In-
formation’s Discharge Abstract Database (DAD), the
Ontario Health Insurance Plan (OHIP) claims database,
the Ontario Drug Benefits (ODB), and the National Am-
bulatory Care Reporting System (NACRS). ICES used
unique encoded identifiers to create the study popula-
tion, to identify occurrence of conditions, and to meas-
ure health service utilization. ICES made the cohort
available on the secure (IDAVE) website for remote ana-
lyses by the researchers. The Lakehead University Re-




We defined MMB as the co-occurrence of any of 16
conditions specified below with any cancer diagnosis,
similar to previous research [4, 37, 38].
Multimorbidity level
We defined and grouped individuals by MMB level as
defined by the presence of one, two, three, four, or five
or more conditions, as compared to cancer only.
Co-occurring conditions
We identified the presence of 16 chronic conditions
using hospital discharge (DAD), physician billing (OHIP)
and drug prescription (ODB) data. These conditions in-
cluded: acute myocardial infarction (AMI), asthma, can-
cer, cardiac arrhythmia, chronic obstructive pulmonary
disease (COPD), congestive heart failure (CHF), chronic
coronary syndrome, dementia, diabetes, hypertension
(HT), non-psychotic mood and anxiety disorders, other
mental illnesses, osteoarthritis, osteoporosis, renal fail-
ure, rheumatoid arthritis, and stroke.
Cancer
We used cancer ICD-O-3 topography and histology
codes and stage indicators available from the Ontario
Cancer Registry (OCR). Cancer type was then defined
according to SEER program [39] for site groups.
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Health services utilization (HSU)
We included several measures of HSU including number
of primary care (PC) visits, emergency department (ED)
visits, and hospital admissions. To account for different
lengths of follow-up and/or death, we defined HSU in
two ways for individuals with more than 30 days of
follow-up post cancer diagnosis: 1) by counts during the
first-year post cancer diagnosis, and 2) average person-
year counts for entire follow-up.
Survival and mortality
Survival was defined as time to all-cause death during
follow-up, using death date from the RPDB. Those with-
out the event were censored at maximum follow-up time
(i.e., systematic treatment of individuals for whom in-
complete information is available), as this is standard
practice for survival analyses [40]. Rate of mortality was
also calculated within 1 year, 5 years, and overall during
follow-up for those who survived at least 30 days post
cancer diagnosis. Mortality was the outcome of interest
for the multivariate regression.
Demographics
Basic demographic variables including age, sex, and geo-
graphic region of residence were obtained from the
RPDB.
Analyses
We used descriptive statistics to characterize population
demographics, common cancer sites, and MMB level.
We then used bivariate and age-stratified analyses to as-
sess cancer complexity relative to participant demo-
graphics, cancer type, HSU, and mortality. Survival
curves stratified by multimorbidity levels and cancer
stage at diagnosis, were created using Kaplan-Meier
method. Finally, we used negative binomial and logistic
regressions to assess the adjusted impact of increasing
cancer complexity on health service utilization and mor-
tality (risk of death) within the first year, using pre-
existing MMB levels (i.e. up to 30 days after cancer diag-
nosis) and controlling for age, sex, cancer types, and
cancer stage at diagnosis. We used SAS v.10 to conduct
all analyses.
Results
Our study population included 601,331 adults diagnosed
with cancer between 2003 and 2013; 49% were females
and 55.7% aged 65 years or older. The most common
types of cancer identified in the sample were (in de-
scending order): Prostate, breast, colon/rectum, and
lung/bronchus (Table 1).
Cancer patients were likely to be complex, with high
levels of MMB
The majority of people with cancer (91.3%) had one or
more co-occurring chronic conditions; nearly one quar-
ter (23.2%) had five or more co-occurring conditions
(Table 1). Complexity was similar between men and
women, but more prevalent among those 65 or more
years of age (Figs. 1a & b). MMB prevalence and levels
varied across cancer types. For example, 9.4% of patients
with cervix uteri cancer had five or more co-occurring
conditions while 36.4% of people with myeloma had five
or more co-occurring conditions (Fig. 1c). Moreover, we
found that overall MMB was associated with stage at
cancer diagnosis (Fig. 1d). For example, the average rate
of no MMB (cancer only) was 8.7% in the population
but 11.1% among people cancer-diagnosed at stage 4.
Relatedly, people with cancer diagnosed at stage 4 had
lower rates of extensive (i.e., 5 or more) MMB condi-
tions (18.4%) compared to the overall population
(23.2%). However, ‘unknown’ cancer stage at diagnosis
accounted for a larger group among those with 5 or
more MMB conditions than lower MMB levels. Also,
those with higher levels of multimorbidity prior to or up
to the time of cancer diagnosis (4, 5+) were more likely
to be diagnosed at cancer stage 4.
Most people (84%) had MMB at the time of cancer
diagnosis (before and up to 30 days after diagnosis).
After cancer diagnosis, 45% of patients developed at least
one additional condition during follow-up; rates of new
chronic conditions after cancer diagnosis were similar
(47%) among those with no MMB at the time of cancer
diagnosis. Overall, 22% of the complex population re-
ceived all MMB diagnoses within the first year of cancer,
and 70% received all of their diagnoses within 5 years
(results not shown).
Health service utilization increased with MMB level,
regardless of patient characteristics
Our design allowed us to follow individuals in the popu-
lation for up to 15 years. During the follow-up period
and, among those with at least 30 days of follow-up ob-
servation, 92% had at least one primary care visit, 41%
had at least one ED visit, and 58% had at least one hos-
pital admission within the first year (Table 1). Utilization
rates during follow-up among those with at least one
service visit was 6 primary care visits, 0.7 ED visits, and
0.5 hospitalizations per year, respectively. The propor-
tion of patients with high use (90th percentile) increased
with increasing MMB. For example, of those with five or
more conditions, 22%, 14% and 28% were high users of
PC, ED visits and hospitalizations, respectively (data not
shown).
HSU was the highest during the first year following
cancer diagnosis. The number of PC visits, ED visits and
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Table 1 Population characteristics: Baseline and follow-up (N = 601,331)
Characteristics N (%)





Rural residency 85,547 (14.2)
Region
Central 190,015 (31.6)






Brain and Other Nervous System 8553 (1.4)
Breast 81,553 (13.6)
Cervix Uteri 5197 (0.9)
Colon and Rectum 71,754 (11.9)
Digestive System, except Colon 49,621 (8.3)
Endocrine System 22,564 (3.8)
Female Genital System, except 30,983 (5.2)
Leukemia 16,996 (2.8)
Lung and Bronchus 75,619 (12.6)
Lymphoma 28,437 (4.7)
Myeloma 8487 (1.4)
Oral Cavity and Pharynx 13,715 (2.3)
Other 39,691 (6.6)
Prostate 87,377 (14.5)
Skin excluding Basal and Squam 23,952 (4)













5 or more conditions 139,217 (23.2)
Follow-up in years: Average (SD); range 5.8 (4.5); 0a - 15
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hospitalizations increased with higher-levels of MMB in
all age groups, in the first year and throughout the
follow-up period (Fig. 2).
The differences between MMB levels in terms of HSU
were more substantial among younger adults, ages 18 to
44 years. In the adjusted models, increasing complexity
was associated with higher rates of HSU, after control-
ling for age, cancer type, stage, sex and number of visits
one year before diagnosis. While there was no clear gra-
dient related to PC visits, those with five or more condi-
tions beside cancer exhibited 51% and 32% more ED
visits and hospital admissions respectively than those
with cancer only (Fig. 3). Individual co-occurring condi-
tions had varying impacts on HSU; however, the effects
of individual conditions appeared less in the presence of
higher levels of MMB (Fig. 4).
Overall, there was a clear gradient in the impact of
cancer stage on all HSU measures, except PC visits
(Additional file 1).
Cancer survival and mortality was associated with cancer
type and age, and MMB had an incremental, independent
negative impact
The overall five-year survival rate among the study
population followed for at least 30 days was 61%, ranging
from 18 to 95% by cancer type. The incremental impact
of MMB, however, was consistent and negative for can-
cer types with similar prognoses. The impact was appar-
ent at any stage, but differences between MMB levels
were more pronounced at earlier stages of diagnosis. An
exception was the limited impact of MMB on survival
among people with lethal cancer types, where diagnosis
was often at later stage (Fig. 5).
About half of the population died during follow-up
and the mortality rate within one year was 19.2% (Table
1). Early death occurred mostly among those with lung/
bronchus, digestive system (except colon) and brain and
other nervous system cancers (data not shown). The risk
of dying within the first year among individuals with be-
tween one and three co-occurring conditions was lower
or similar to those with no condition prior to cancer
diagnosis, whereas those with five or more conditions
were 45% more likely to die, regardless of age, sex, can-
cer type or stage (Additional file 1). Mortality was higher
for stage 2 (IRR = 2.3) and stage 4 (IRR = 23.3) compared
to stage 1.
The impact of individual chronic conditions was
largely different within and between levels of MMB. For
example, the risk of death varied from 0.43 (osteopor-
osis) to 2.33 (renal disease) among those with one condi-
tion prior to cancer, and from 0.85 (hypertension) to
1.49 (CHF) among those with five or more conditions
prior to cancer (Fig. 4). Surprisingly, COPD decreased
the risk of death by 17% when present alone before can-
cer, while increasing the risk of death by 37% when
present with at least four other conditions.
Detailed results of the adjusted impact of MMB on
HSU and mortality overall and by age group are in Add-
itional file 1 - Appendices 1 and 2.
Discussion
This population-level study is among the first to exam-
ine the co-occurrence of cancer of all types and 16 other
chronic conditions managed outside of the cancer care
system. While research on MMB continues to grow,
there are only few studies assessing the number of co-
occurring conditions among people with cancer, and
those studies have typically included only a few specific
cancer sites [7, 8, 11]. By describing the extent of MMB
within cancer of all types, we aim to inform Canadian
and global efforts to improve quality, efficiency, and
Table 1 Population characteristics: Baseline and follow-up (N = 601,331) (Continued)
Characteristics N (%)
Health service use within the first year (follow-up > =30 daysb)
Primary care visit: at least one 519,752 (92.2)
Primary care visit: High use (90th pct, i.e. > = 15) 63,835 (11.4)
ED visit: at least one 228,280 (40.7)
ED visit: High use (90th pct, i.e. > 3) 57,239 (10.2)
Hospital admission: at least one 325,513 (58.1)
Hospital admission: High use (90th pct, i.e. > = 2) 127,976 (22.8)
Mortality (follow-up > =30 days)
Within first year 107,378 (19.2)
Within five years 219,315 (39.1)
Overall, during follow-up 281,268 (49.8)
a7503 with follow-up = 0; all deceased same day as cancer diagnosis (93% with at least another condition, 15% with 4 conditions and 30% with 5 or more
conditions). b 40,761 with follow-up< 30 days (i.e. died within 30 days) excluded
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Fig. 1 Multimorbidity level by sex, age, cancer site and stage
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patient outcomes and experiences in complex (i.e., mul-
timorbid) cancer care.
Overall, the prevalence of MMB in cancer patients is
among the highest [4, 41]. Similar to previous studies [7,
11], we found that cancer MMB was extremely common
(91%) in our population of patients diagnosed with can-
cer between 2003 and 2013. MMB was also present
across all stages of cancer, with some indication that
MMB prior to cancer was related to diagnosis at later
stages, but the overall proportion of extensive MMB was
lower at later cancer stage, likely due to survival bias or
lack of focus on other conditions following cancer
diagnosis. Our data also showed that rates of cancer
MMB remained stable over time, indicating the ongoing
need to address MMB effectively.
While patients are likely to exhibit multiple conditions
before cancer, MMB continues to increase substantially
after a cancer diagnosis. In our study, we found that
nearly half of all people with cancer were diagnosed with
an additional chronic condition during follow-up. This is
consistent with data from Leach and colleagues [7] in
which cancer patients reported the emergence of ap-
proximately 1.9 new conditions after diagnosis of one of
five common cancer types.
Fig. 2 Health Service Utilization (HSU) by MMB level, prior to and following cancer diagnosis, by age, among those with at least 30 days of
follow-up (n = 560,570)
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Our data is also consistent with previous studies show-
ing no sex difference in MMB rates but increased rates
and levels of MMB among older age groups [9, 11]. Not-
able from our study, however, are findings that cancer
MMB was observed across all age groups, including high
rates of cancer MMB with two or more conditions in
young adults (ages 18–44 years). This suggests that
MMB is not only an issue for older adults but a growing
issue for adults of all ages [4, 41–43].
Cancer sites with the highest prevalence of MMB were
myeloma, prostate, urinary system, lung/bronchus and
Leukemia. For example, those with four or more condi-
tions beside cancer represented a substantial proportion
for all sites of cancer from 19% (cervical cancer) to 53%
(myeloma). Similar to our study, Fowler et al. [11] found
that MMB was higher among people with lung cancer
compared to the other four cancers included in their
study, with 67% of lung cancer patients having one or
more comorbidities. Different from Fowler and col-
leagues, however, is that our overall rates of MMB are
higher. An important difference between our methods is
that Fowler et al. [11] considered four possible co-
occurring conditions instead of the 16 included here.
Other contextual factors, such as public health screening
initiatives, may also be important for between-population
and between-cancer rates of MMB. For example, in
Ontario, Canada, cervical cancer was among the sites with
the lowest prevalence of MMB in our study (66% before
cancer and 82% overall) but it is also the target of a
province-wide screening initiative for women as young as
age 21 [44] who are less likely than older adults to have
MMB.
We also analyzed the impact of MMB on multiple as-
pects of the HSU. While adequate access to primary care
may contribute to better care management and patient
outcomes, high use of ED and hospital services, and ul-
timately death, reflect poor patient health which may be
aggravated by the presence of multiple conditions. Not
surprisingly, both mortality and HSU were positively as-
sociated with increasing MMB levels in our study, re-
gardless of patients’ age, sex, cancer type or cancer stage.
This is in line with previous research showing that
higher MMB was associated with a higher risk of death
or lower survival among patients with specific cancer
types [6, 12, 45]. Legler et al. (2011) also found a positive
association between high patient Charlson Comorbidity
Index and increased admission to ED, hospital, and ICU
[46]. Unlike prior work, a unique contribution of this
paper is that we examined the relationship between
MMB level and HSU. In those analyses, we observed
Fig. 3 Adjusted impact of MMB on the number of health services encounters, overall and by age groups. Incidence rate ratio (IRR) values are
displayed for the overall population and all analyses were adjusted for age, cancer type, stage, sex and number of visits one year before diagnosis
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that increasing MMB level had a greater negative impact
on HSU among younger people: the difference between
cancer only and the highest level of MMB was on aver-
age 1.8 ED visits and 7.1 PC visits in young adults com-
pared to 0.4 and 4.3 among people 65 years and older.
The trend was opposite for mortality: increasing MMB
was not as strongly linked to risk of death among younger
adults. More research examining potential contributing
factors, such as early screening and identification through
regular health service use, for example, is needed to better
understand cancer MMB in younger adults.
Lastly, our data showed that individual conditions
had varied impacts on patients’ health outcomes, de-
pending on the level of MMB. Conditions frequently
identified as co-occurring with cancer in previous
studies include hypertension, COPD, diabetes, CVD,
and CHF [11, 46]. These conditions were also among
the most frequent in our study population. The most
common co-occurring conditions (hypertension, arth-
ritis, anxiety, diabetes) often had the greatest impact
on outcomes; however, other less prevalent conditions
are also worth considering. Overall, the relationship
between cancer, mental health (including substance
use disorder) diagnoses, and HSU is in need of fur-
ther study. Our data showed increased PC encounters
among people with co-occurring anxiety disorder,
which was also associated with fewer hospitalizations
and a lower risk of death. While it well known that
psychiatric conditions are a significant driver of HSU
(e.g., [47]), conditions like anxiety that increase pre-
ventive contacts with the healthcare system may rep-
resent a protective form of MMB. Other conditions
such as dementia or psychosis that limit patient cap-
acity for self-care, in comparison, may increase
higher-acuity service use, such as ED visits and hospi-
talizations, signaling the need for more intensive pre-
ventive care and/or illness self-management supports.
Overall, these findings suggest that while MMB is im-
portant to understand overall, unique combinations of
co-occurring conditions are likely to have differential
effects on HSU and patient outcomes, and thus re-
quire further study.
Strengths and limitations
This is the first population-based cohort study to exam-
ine the burden of MMB and its impact in the Ontario
population of people with all types of cancer. It presents
many strengths, including the size of the study popula-
tion, extended follow-up of between five and 15 years,
and the use of administrative data including multiple
chronic conditions, including indicators of mental
health. Because Ontario has universal health coverage,
Fig. 4 Incidence rate ratio (IRR) shows the impact of pre-existing individual conditions on health service use and mortality, by MMB levels. All
analyses were adjusted for age, cancer type, stage, sex and number of visits one year before diagnosis. Prevalence of each condition in the study
population is provided between bracket. For example, 5.1% of those who survived at least 30 days had been diagnosed with renal disease prior
to cancer; 54.1% with hypertension, etc. As shown, impact of each condition greatly varies by MMB level and between conditions within the
same level
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Ontario’s health administrative data provide robust,
population-based estimations of cancer MMB [48] not
available from self-report or other sources. In fact, with
comprehensive health administrative data, estimates of
MMB are more likely to be reliable and complete than
patient self-report [49]. In this study, we operationalized
MMB through 16 high-burden chronic conditions, both
prior to cancer and for five or more years following can-
cer diagnosis. Most of these chronic conditions were op-
erationalized using validated algorithms; however, some
conditions may not be adequately represented [50, 51].
Namely, studies have found mixed results related to the
under- or over-diagnosis of co-occurring conditions in
cancer patients [52, 53]. Though the number of
conditions is adequate to assess overall MMB [54], an-
other limitation is that other potentially relevant chronic
conditions were not included which could have unique
effects as individual diseases and/or as part of the effects
of MMB level. Another limitation of this report is that
the severity of non-cancer conditions is not considered
in our assessment.
In addition to our main objective of describing MMB in
cancer patients, we also aimed to advance the understand-
ing of MMB on HSU and mortality. To do this, our ana-
lysis included only basic patient demographics and an
indicator of cancer severity, which is sufficient to describe
baseline impacts of MMB and develop hypotheses and ra-
tionale for further research. That said, we acknowledge that
Fig. 5 Kaplan-Meier survival curves by multimorbidity and stage at diagnosis for selected cancer types
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many other potentially confounding variables, such as so-
cioeconomic status, could have potentially impacted our
results and as such may be important in future work.
There may also be some residual confounding regarding
cancer stage because of the limitations in the staging data
and the large proportion of missing information (presented
as unknown); however, we believe that this approach is ad-
equate to support the exploratory nature of this work. We
also did not examine treatment approaches and quality of
care that can play a crucial role in cancer outcomes.
Conclusions & Implications
People with cancer are very likely to experience MMB
over all and at very high levels, regardless of age and
cancer type – including young adults whose risk for
MMB may have been previously overlooked. The find-
ings in this report can inform health system advances to-
wards person-centered care as it describes the overall
nature MMB for the whole range of cancer types. At the
same time, our findings also show that there is wide
variation in the impact of individual conditions within
and between MMB levels, suggesting that it is crucial to
assess the role of each condition within a MMB lens.
This could, for example, include routine assessment of
chronic conditions that commonly co-occur with cancer
and coordinated care pathways that reduce treatment
burden and increase access to targeted supports (e.g.,
mental health; illness self-management) for patients
likely to experience the need. More generally, however,
our findings show that at higher levels of MMB, individ-
ual conditions have less of an impact on outcomes that
MMB itself, again highlighting the need to improve how
care for people with MMB is envisioned and operation-
alized. In the next paper, we describe the relationship
between specific, observed clusters of cancer and chronic
diseases and their relationship to HSU and mortality risk
to help guide next steps in advancing MMB care.
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